3P Biopharmaceuticals appoints Kenneth McMahon as Head of Quality Control

Kenneth McMahon has a PhD in molecular microbiology and a solid experience of over 10 years in both Quality Assurance (QA) and Quality Control (QC) departments.

3P Biopharmaceuticals (3P), a leading organization specializing in the development of cGMP processes and manufacturing of biological products (CDMO) appoints a new member as head of quality control.

Kenneth McMahon has a PhD in molecular microbiology and a solid experience of over 10 years in both Quality Assurance (QA) and Quality Control (QC) departments. He joined 3P with the objective of controlling and ensuring the correct quality of the manufactured products as well as compliance with the approved safety criteria.
He began his professional career in quality control at Genzyme (now Sanofi). In 2015 he joined the quality department at Bristol Myers Squibbs and since then he has continued to develop his knowledge and skills in the field of pharmaceutical quality.

After that, he worked for 4 years in positions of responsibility within the Quality Assurance and Quality Control departments at Samsung Biologics.
His professional career has been developed in GMP environments, and he is an expert in the design, development, and implementation of pharmaceutical quality systems, as well as in the management and quality control of pharmaceutical products.

3P Biopharmaceuticals appoints Kenneth McMahon as Head of Quality Control

“Joining a company like 3P is a fantastic opportunity to further develop my career and to be able to move back to Europe. I look forward to contributing successfully to their quality strategy”. Kenneth said on his arrival at the Noáin-based company.
Dámaso Molero, CEO of 3P Biopharmaceuticals said: “As an international company, we are excited to welcome Kenneth to our team. His extensive experience in senior quality positions will undoubtedly help us to strengthen the area to continue providing a high level of service”.

Therefore, with this new addition to the quality department, 3P continues its growth plan and consolidates its competitive position as one of the leading CDMOs in Europe.

View the full press release here

Our dedicated team of specialists will be happy to discuss any of your CDMO supply chain needs. Contact us on +34 948 346 480 or email withinus@3pbio.com

Related Content

3P Biopharmaceuticals continues its successful collaboration with Toleranzia AB to fight Myasthenia Gravis.

Published: 19th September 2023
Toleranzia is at the forefront of innovation with their groundbreaking candidate, TOL2, designed to address the autoimmune neuromuscular disease, Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals lands in the United States.

Published: 8th June 2023
The Navarre biological CDMO inaugurates its first commercial office in Boston, supported by Keensight Capital.
Read more

3P Biopharmaceuticals continues its collaboration with U.S. biotech Zhittya for the treatment of Parkinson’s disease.

Published: 2nd May 2023
The process transfer and GMP supply of the FGF-1 candidate have been achieved successfully by both companies.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.